Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Sonnet BioTherapeutics, Inc. Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy July 22, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers July 21, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition June 09, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum June 02, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update May 10, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Tickers SONN Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors April 13, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting April 08, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors March 16, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Tickers SONN Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting February 09, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update February 08, 2022 From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Tickers SONN Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update December 17, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) August 30, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering August 19, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory Tickers SONN Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update August 16, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Tickers SONN Sonnet BioTherapeutics Announces Change in Date of Annual Meeting June 14, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology June 08, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers SONN Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update May 17, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) May 10, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Tickers SONN Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics May 03, 2021 From Sonnet BioTherapeutics, Inc. Via AccessWire Tickers SONN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.